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Introduction
Cardiac dysfunction in cirrhosis is receiving increasing attention. The term Cirrhotic cardiomyopathy (CCM) describes a clinical entity of impaired systolic responsiveness to stress, diastolic dysfunction, and electrophysiological abnormalities observed in patients with cirrhosis 1 .
Importantly, CCM has been associated with the development of renal failure and poor prognosis.
However, the underlying pathophysiology of CCM is still largely unresolved. Results from autopsy studies suggest that structural cardiac abnormalities including diffuse myocardial fibrosis may be involved 2 . Cardiac magnetic resonance (CMR) with measurement of the longitudinal relaxation (T1) times is able to assess myocardial tissue characteristics such as infiltration, edema, and fibrosis. The quantification of the myocardial extracellular volume fraction (ECV) by use of native and post-contrast T1 maps has been histologically validated with a strong correlation to diffuse myocardial fibrosis 3 . Myocardial ECV has been shown to be a strong predictor of poor outcome in several cardiac diseases including cardiomyopathies, heart failure, and diabetes 4 . The present study is the first to apply myocardial ECV quantification in patients with cirrhosis. The purpose of this study was to use CMR with myocardial ECV quantification to explore the presence of diffuse myocardial fibrosis in patients with cirrhosis. We hypothesized that CMR-derived myocardial ECV is increased in cirrhosis indicating diffuse myocardial fibrosis, and that myocardial ECV relates to disease progression, cardiac function, and poor outcome. ongoing infections (n=3), impaired renal function (estimated glomerular filtration rate < 45 ml/min/1,73m 2 ) (n=6), previous transjugular intrahepatic portosystemic shunt or liver transplantation (n=2), malignancy (n=2), anti-viral hepatitis C medication (n=5), contraindications to CMR or contrast-agents (n=5), refused participation (n=7) or were considered incapable to adhere to the study protocol due to heavy drinking(n=10). All patients underwent clinical evaluation, blood sample collection, 12-lead ECG, tissue Doppler echocardiography, contrastenhanced CMR and a CT coronary angiography in the same day. The latter was obtained in order to exclude presence of undiscovered ischemic heart disease. In order to reduce confounding factors diuretics and beta-blockers were withdrawn 48 h prior to the investigations. The cohort included a total of 63 patients; however ECV quantification was not performed in 11 patients due to poor compliance in the scanner, or lack of intravenous access. These patients were excluded for this substudy. A group of 10 healthy age and sex matched subjects without known cardiovascular risk factors and with a completely normal CMR scan, served as controls. The control group did not undergo further investigations.
Patients and Methods

Cardiac magnetic resonance imaging
Cine CMR. All participants received clinical CMR scans by dedicated CMR technologists with a 3.0-Tesla Siemens Magnetom Verio (Siemens Medical Solutions, Erlangen, Germany) and a 32channel phased array cardiovascular coil. The examination included standard breath hold segmented cine imaging with steady state free precession. Left and right ventricular dimensions, myocardial mass, cardiac output (CO) and cardiac index (CI) were measured from short axis stacks of end diastolic and end systolic cine frames.
T1 mapping and ECV quantification. T1 mapping was performed with electrocardiographically triggered MOLLI with a 5(3)3 prototype on a short-axis view. This method generates an inline, pixel-based T1 map by acquiring a series of images over several heartbeats with shifted T1 times, inline motion correction, and inline calculation of the T1 relaxation curve within one breath hold.
T1-sequence parameters were as follows: starting inversion time (TI) 120 ms, TI increment 80 ms, reconstructed matrix size 360 x 307 ( phase-encoding resolution 66%, phase-encoding field of view 85.2%). T1 maps with motion correction were created before and 8 min after gadolinium application. For post-contrast T1 mapping, a 4(1)3(1)2 prototype was used. Post processing was performed using dedicated software (cmr42, Circle Cardiovascular Imaging Inc., Calgary, Canada). T1 values (in milliseconds) were obtained by drawing regions of interest around the entire myocardium in a single midventricular slice and in the blood pool on the corresponding pre-and post-contrast images. Care was taken to secure a sufficient distance to tissue interfaces. ECV was calculated with the formula 5 : ECV in % = ƛ x (1hematocrit). Where ƛ = (∆ R1 myocardium)/ ∆ R1 blood) and ∆ R1 = (1/post-contrast T1) -(1/pre-contrast T1). Normal values were obtained in the 10 healthy volunteers.
Reproducibility of myocardial ECV. For intraobserver variability, the same operator repeated the measurements in 25 studies in anonymized form, more than 8 weeks after the initial analysis. For interobserver variability, a second operator re-analyzed the images of the entire cohort in anonymized form. Intra-and interobserver variability of ECV was 0.1± 2.4% and 0.4 ± 2.9 %, respectively.
Echocardiography. Transthoracic tissue Doppler echocardiography was performed by two experienced echocardiographers using a commercially available system (Epiq 7G, Phillips, Andover, USA). Left ventricular inflow velocities were determined using pulsed-wave Doppler with a 4 mm sample placed between the tips of the mitral leaflets during diastole at end-expiration.
The following parameters were measured: isovolumetric relaxation time, peak early filling and its deceleration time, atrial filling peak, and E/A ratio. Mitral annulus tissue velocities (e') were acquired by pulse-wave tissue-Doppler imaging with the sample volume placed at the septal and lateral mitral annulus. The E/e' ratio was calculated using the average e'. The left atrial volume was determined by area-length method from end-systolic apical four-chamber and two-chamber views.
Left atrial maximum volume index (LAVI) was averaged from both views and corrected for body Biomarkers. Blood samples were obtained from the cubital vein, and plasma was stored at -80 ºC.
High-sensitivity troponin T (hs-TnT) and probrain natriuretic peptide (proBNP) were measured on an automated Modular E platform (Roche, Mannheim, Germany). Mid-regional proatrial natriuretic peptide (proANP) was measured on a Kryptor Plus platform (Thermo-Fisher, Waltham, USA).
Copeptin (provasopressin) was analyzed with a standard sandwich immuno-luminometric assay (Thermo-Fisher, Waltham, USA Brahms). We have previously reported on assay performance and characteristics 6 . Renin was estimated with a commercially available immunoradiometric assay (DGR International, Hamburg, Germany). LLQ was 0.31 g/mL, intra-and inter-assay imprecision was 2%. Noradrenaline and adrenaline were measured as the stable metabolites methoxynoradrenaline and methoxy-adrenaline using a commercially available kit (Acquity UPLC IClass Xevo TQ-S; Waters Corporation, USA) with a LLQ of 0.1nmol/L. Follow-up registration and poor outcome. All patients were prospectively followed up at 6-month intervals by ambulatory visits, telephone calls or review of the medical files. Poor outcome was defined as the composite end point of liver transplantation (LT) and death.
Statistics. Data were stored and analyzed using SPSS Statistics 22 (IBM Corp., NY, USA). The results are reported as median (25 th -75 th percentile), mean ± SD or as n (%) as appropriate. The Student t, Mann-Whitney, or chi-squared tests were used to compare continuous or categorical variables. One-way analysis of variance (ANOVA) was used to compare multiple groups. In cases of non-normality, the non-parametric Kruskal-Wallis ANOVA was applied. Correlations were performed by the Spearman rank test to investigate possible interrelation between variables.
Follow-up data was analyzed by using Kaplan Meier plots with log-rank tests for group comparisons. Univariate and multivariate proportional hazard Cox regression analyses were performed to evaluate the association of myocardial ECV and well-known prognostic variables with transplant-free survival. All reported P values are two-tailed with values less than 0.05 considered statistically significant. Patients were divided into two groups according to their myocardial ECV to separate those with the highest ECV, and compared with respect to cardiac function, poor outcome, and transplant-free survival. The cut off for purposes of dividing the patients was pragmatically chosen as the mean myocardial ECV 31.2 %, though supported by the range of abnormal ECV values reported in patients with cardiomyopathies, systemic inflammation and diabetes 4, 7 .
Results
The study included 52 patients with cirrhosis. In Table 1 Table 2 . Patients with cirrhosis had a higher cardiac index than healthy controls, whereas no significant differences were seen in respect to the cardiac dimensions. Patients with advanced cirrhosis (Child Pugh > 7) displayed markedly increases in end-diastolic volumes of both left and right ventricle resulting in an increased stroke volume, CO and CI in comparison to patients with less advanced cirrhosis (Child Pugh ≤ 7). Myocardial ECV was increased in patients compared with healthy controls (31.2±6 vs. 27.4±3 %, P =0.04).
Moreover, myocardial ECV was higher in patients with advanced cirrhosis in comparison with both healthy controls and patients with less advanced cirrhosis as shown in Figure 1 . Additionally, myocardial ECV increased across Child Pugh classes (26.9±4/ 31.5±5/ 34.4±6%, P=0.02). No significant differences in myocardial ECV were seen neither when data was stratified according to alcohol vs. non-alcohol etiology, use of beta-blockers or statins, nor according to established cardiovascular risk factors such as smoking, diabetes, arterial hypertension, and hypercholesterolemia (P=NS). Echocardiographic parameters are listed in Table 3 . Left ventricular DD was present in 19 patients (37%) with grade 1 DD in one patient and grade 2 DD in the remaining. No patients had grade 3 DD. Moreover, left atrial enlargement (LAVI >34 ml/m 2 ) was present in 21 patients (33%) and an increased E/e' ratio ≥ 10 in 17 patients (32%) pointing towards an increased left ventricular filling pressure. Resting systolic function was impaired (LVEF<55%) in 2 patients, one of these also had DD. Accordingly; CCM was diagnosed in 20 patients (38%). Table 5 compares patients with a high myocardial ECV (> 31.2%) to those with a low ECV (≤ 31.2%). Patients with a high ECV differed with respect to the following: Lower albumin, higher CRP, higher levels of natriuretic peptides, a higher cardiac output and cardiac index, increased E/A ratio, E and lateral e' (P<0.05). The use of beta-blockers or statins did not affect neither the outcome nor the presence of increased myocardial ECV, P=NS.
ECV in relation to
Transplant-free survival was significantly greater in patients with a low myocardial ECV compared to those with a high myocardial ECV (86 vs. 57%, p=0.02). Figure 2 shows the probability of transplant-free survival stratified according to myocardial ECV with a lower transplant-free survival in the high ECV group. Moreover, if patients were stratified both according to their median MELD and myocardial ECV, those with a high MELD and a high myocardial ECV tended to have a poorer transplant-free survival (Suppl. Figure S1 ). In Table 6 is shown univariate proportional hazard Cox regression analyses and a high myocardial ECV was associated with increased risk of poor outcome HR= 3.6 (95% CI =1.1-11.6), P=0.03. However, when ECV and well-known prognostic variables in cirrhosis were included in a multivariate proportional hazard Cox regression analysis MELD and CRP remained the strongest markers independently associated with poor outcome. The causes of death were: Sepsis (n=4), hepatorenal failure (n=1), liver failure/cirrhosis (n=1), alcoholic hepatitis (n=1), intracerebral bleeding (n=1), and unknown in 2 patients who were found dead at home. Interestingly, myocardial ECV was high in the patients with unknown cause of death (33% and 35%, respectively). These patients also had increased levels of natriuretic peptides, and QTc was prolonged in one (468ms) and borderline in the other (438ms).
Discussion
This study is the first to investigate expansion of the myocardial extracellular volume in patients with cirrhosis using CMR. We show that patients with cirrhosis have an increased myocardial ECV.
We also establish a significant relationship between myocardial ECV and severity of the liver disease. Finally, an increased myocardial ECV seemed to be related to poor prognosis. These ECV and systolic dysfunction. The hyperdynamic circulation has been proposed as an important element for the development of CCM. The high cardiac output is a result of the vasodilatory state and tends to maintain a sufficient perfusion in the vital organs. However, this may inflict cardiac strain due to the increased cardiac work which over time causes the development of cardiac dysfunction 1 . In our study the relationship between markers of a hyperdynamic circulation and myocardial ECV was ambiguous, but we revealed a strong association between myocardial ECV on the one hand and a high cardiac index and increased plasma renin levels on the other. This may indicate important pathophysiological implications, which need to be investigated further. A resting systolic dysfunction was only present in two patients and both of these patients had a normal myocardial ECV. A plausible explanation to this finding is that our study population consisting primarily of stable cirrhotic outpatients in whom systolic dysfunction was only latent. In future studies it would be relevant to apply pharmacological stress in order to unmask subclinical systolic impairment.
ECV and diastolic dysfunction. Post-contrast T1-times have been related to DD with a close correlation to E/e' in patients with hypertrophic cardiomyopathy 13 . Similarly, a recent study in cardiac transplant patients reported an association between an increased myocardial ECV and increased left ventricular wall stiffness, thereby linking intrinsic myocardial alterations to the mechanism of DD 14 . We found no relations between myocardial ECV and DD in our study, although the myocardial ECV of patients with an increased E/e' tended to be higher. It is however most likely that our stable cirrhotic patients from a hemodynamic point of view are different from those of patients with hypertrophic cardiomyopathy or cardiac transplant, respectively. It may therefore be a key issue to study the relationship between myocardial ECV and DD in patients with more advanced cirrhosis as recent studies have reported pronounced DD in these patients 15, 16 .
ECV and poor outcome. An unfavorable relationship exists between myocardial ECV and outcome
in patients with non-ischemic cardiomyopathy as well as in diabetes in terms of development of heart failure, cardiac mortality, and overall survival 4 . Similarly, we found indications pointing towards an association between increased ECV and poor outcome in patients with cirrhosis. We defined poor outcome as the combined endpoint of death or LT as we consider the need of organ replacement as an indicator of markedly disease deterioration. However, in the multivariate Cox regression analysis MELD and CRP remained the strongest independent predictors of survival, which is not surprising as both disease severity and inflammation repeatedly have been shown to have great impact on survival in cirrhosis 17 . It is important to be aware that the statistical power may not be sufficiently strong to perform a final evaluation of the relationship between myocardial ECV and outcome measures because of the limited number of endpoints. Therefore, the seemingly associated poor outcome needs to be confirmed in larger studies. The absence of an association between ECV and portal hypertension may in part be due to the time gap between measurements of HVPG and cardiac measures, which in some patients were more than 6 months.
Limitations. Although our study is a prospective study with application of advanced cardiac imaging techniques it has some limitations. Firstly, this is a single center study in a selected study population comprising predominantly stable outpatients due to several exclusion criteria. These criteria resulted in a considerable number of screening failures, but were chosen in order to eliminate potential confounders on cardiac function and survival. Moreover, the majority of our patients had cirrhosis on the basis of excessive alcohol intake. Thus our results may not be applicable to the general population of cirrhotic patients and need to be validated in larger studies including patients with more advanced cirrhosis and non-alcoholic etiologies. Secondly, we used a 3.0 T MR scanner which is more prone to artefacts due to the strong magnetic field. However, the mean ECV value in our healthy controls was similar to the 3.0 T reference values reported by others 18 . This indicates that our ECV estimates are reliable. Third, we cannot verify that the increased myocardial ECV in cirrhotic patients is solely due to presence of diffuse fibrosis as presence of edema and infiltration may also expand the myocardial extracellular space thereby leading to an increased ECV. However, CMR-derived ECV correlates well to histologically diffuse myocardial fibrosis in endomyocardial biopsies from patients with non-ischemic heart failure 19 .
Since these patients and cirrhotic patients share the clinical feature of fluid accumulation we believe that these results are transferable to cirrhosis. Furthermore, our myocardial ECV values are similar to those reported in both patients with cardiomyopathies (ECV: 31-41%), systemic inflammation (ECV: 30%), and with diabetes (ECV: 30.2%) 4, 7 . Therefore, we consider the differences in myocardial ECV reported in our study of clinical significance, but confirmation in future studies is needed.
Conclusion
Myocardial ECV as determined by CMR is increased in cirrhotic patients indicating an expansion of the myocardial extracellular volume. These changes most likely reflect subclinical diffuse myocardial fibrosis and seem associated with disease severity. In addition the structural changes seem to possibly influence the prognosis. Hence, these preliminary findings indicate myocardial abnormalities as an element of CCM and the potential implication of this finding should be further explored. 
